A combination of levobunolol and dipivefrin for the treatment of glaucoma

R. C. Allen, A. L. Robin, D. Long, D. Novack, J. C. Lue, G. Kaplan

Research output: Contribution to journalArticlepeer-review

Abstract

This double-masked prospective study compared the ocular hypotensive efficacy and the safety of 0.5% and 1% levobunolol hydrochloride with 0.5% timolol maleate when each was administered topically twice daily in combination with 0.1% dipivefrin hydrochloride. Forty-three patients whose intraocular pressure was previously controlled by concomitant treatment with timolol and dipivefrin were randomly assigned to receive 0.5% or 1% levobunolol and 0.1% dipivefrin, or to continue to receive 0.5% timolol and 0.1% dipivefrin for three months. In the groups receiving levobunolol and dipivefrin concurrently, continued intraocular pressure control was achieved equal to that attained with timolol and dipivefrin before study entry. We concluded that concomitant treatment with levobunolol and dipivefrin is equal in both efficacy and safety to concomitant treatment with timolol and dipivefrin.

Original languageEnglish (US)
Pages (from-to)904-907
Number of pages4
JournalArchives of ophthalmology
Volume106
Issue number7
DOIs
StatePublished - 1988
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'A combination of levobunolol and dipivefrin for the treatment of glaucoma'. Together they form a unique fingerprint.

Cite this